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Abstract. The aim of this review was to define appropriate
11B delivery agents for boron proton-capture enhanced proton
therapy (BPCEPT) taking into account the accumulated
knowledge on boron compounds used for boron neutron
capture therapy (BNCT). BPCEPT is a promising treatment
approach which uses a high linear energy transfer (LET) dose
component in conjunction with conventional proton therapy to
increase the relative biological effectiveness of highly-selective
charged particle therapy. Boron proton fusion reactions occur
with highest cross section at certain proton energy level and
thus can be tailored to the target volume with careful
treatment planning that defines the 675 MeV proton
distribution with high accuracy. Appropriate 11B compounds
are required in order to achieve relevant high LET dose
contribution from the boron proton-capture reaction. Previous
scientific results and experiences with BNCT provide
background knowledge and information regarding the
optimization of boronated compound development, their
characterization, measurement and imaging. However, there
are substantial differences between BNCT and BPCEPT,
which in turn places special unique chemical, physical and
biological demands on 11B-carrier compounds for BPCEPT.
In this review, we evaluate well-known and recently developed
boron compounds for BPCEPT.
The electrostatic and physical properties of accelerated,
charged nuclear particles (protons, heavy ions) enable their
accurate submillimeter dose delivery in cancer therapy (1).
This results in high tumor tissue selectivity and enhances the
therapeutic index for patients with cancer. There is also an
additional ~10% increase compared to photon therapy in the
relative biological effectivity of a proton beam (averaged on
the particle path length) and a two- to three-fold increase in
the relative biological effectivity of densely ionizing heavy
ions (2). The immense installation, maintenance and
operational costs have prevented the spread of heavy-ion
therapy; however, compact hospital-based cyclotrons/
synchrocyclotrons, due to superconducting techniques (3),
can be more cheaply installed, increasing the availability of
proton therapy for oncology and providing a basis for well
designed multicenter clinical studies. There is an ever-
growing body of evidence on the greater value of proton
therapy over the best available photon irradiation modalities.
This stronger standing is supported by computational
investigations, which have proven the superiority of the dose
distribution of proton therapy for a wide range of malignant
diseases (4) and in clinical evaluation for childhood
malignancies, and in the treatment of radioresistant tumors
and of tumors in close proximity to radiosensitive structures.
Clinical studies on carbon-ion therapy are also very
promising and confirm the enhanced biological effectivity
detected in preclinical studies, but a similar increase in the
number of ion centers is not anticipated to the extreme cost
for implementing heavy particle acceleration. Therefore, a
method to increase the relative biological effectiveness of
proton beam is of high interest in radiation oncology. Boron
proton-capture enhanced proton therapy (BPCEPT), a novel
approach, has emerged from alternative particle acceleration
research for enhancing the biological effectiveness of proton
therapy. A high linear energy transfer due to the boron
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proton-capture (BPC) reaction working in conjunction with
a proton dose delivery might result in well-directed
enhancement of the biological effect in defined sub-regions
of the target volume. This binary approach can be optimized
by the careful tailoring of the proton beam parameters and
the selection of nontoxic 11B delivery agents with high and
favorable subcellular accumulation. Our main aim in this
review was to analyze boron carriers from the first to the
third generation used for boron-neutron capture therapy
(BNCT) in order to define the most appropriate 11B delivery
agents for BPCEPT. 
The highest probability for the most effective combination
of BPC and proton dose occurs at a discrete proton energy
level of 675 keV (5-9). Accessing this energy requires an
initial proton deceleration to a certain position along the
proton dose–depth curve (under the Bragg peak or at the end
of the spread of the Bragg peak) and thus the BPC reaction
can be defined with submillimeter accuracy. The additional
dose enhancement generated by BPC depends on the proton
intensity and intracellular 11B concentration. The biological
effect is also highly affected by the intracellular micro
distribution of 11B due to the short energy deposition range
of the alpha particles emitted by the reaction p + 11B → 3α. 
Boron Proton Capture 
Clean energy production research has focused on nuclear
fusion reactions potentially obtained from high-intensity-
pulsed laser technology. Boron–proton fusion was one of
these studied reactions as it is highly energetic (8.7 MeV),
is free from high-energy neutrons and generates three alpha
particles. The initial reaction between 11B and a proton
results in an excited carbon atom (12C) which splits into an
alpha particle (3.76 MeV) and a beryllium (8Be) atom, which
subsequently divides into two alpha particles (2.74 MeV).
The highest cross section for this reaction occurs with
protons with energies around 600-700 keV. 
This has led to the idea of exploiting all the advantages of
BPC during cancer proton therapy. The first publication on
BPC in radiation therapy used Monte Carlo simulations and
showed an enhanced high dose in the areas where the boron
uptake coincided with the Bragg peak (5). There are a few
other studies which used Monte Carlo simulations, but which
produced highly divergent results on the potentially
achievable BPC dose, ranging from 0.026% to 0.3% based
on using different proton energies and 11B concentrations (5-
8). The first cell culture experiments were performed at the
medical cyclotron in Catania and showed that the BPC
procedure increased the biological effectivity of proton
irradiation (9). There was a significant enhancement effect
on both the cell survival test based on a colony-forming
assay and chromosome aberration analysis due the presence
of naturally-occurring 11B present in sodium borocaptate
(Na2B12H10-SH; BSH). Such a promising approach requires
further investigation.
Therapy using BPC, in contrast to BNCT, does not require
such a high differential boron uptake in the target region
because proton irradiation is highly spatially selective. This
ensures that the majority of BPC will be within the planned
region, even in the case of homogeneous boron distribution
in a larger volume around the target region (10). To that end,
the proton energy distribution must be calculated with high
accuracy and should be tailored to the volume of interest
where the BPC enhancement is required. A high and long-
lasting tumor concentration of 11B and favorable intracellular
micro-distribution, preferably close to radiosensitive cell
elements (nucleus, mitochondria, membrane) are needed for
successful BPCEPT. The vast amount of research and
experience with boron compounds used in BNCT is an ideal
starting point for seeking optimal boron compounds for
BPCEPT research. 
Boron Compounds Used in BNCT
BNCT uses the high cross section (3840 barns) of 10B to
capture thermal neutrons producing two alpha (α, 4He2+)
particles and a 7Li particle – 10B + nth → [11B]*→ α + 7Li
+ 2.3 MeV. The fission products deliver energy in tissue to
a depth of ≈9 μm and ≈5 μm, respectively, which is highly
biologically effective. The therapeutic potential of the boron
neutron capture reaction was first recognized by Locher in
1936 (11) and clinical studies started in the early 1950s.
Twenty years after the first unsuccessful human applications
(11, 12), intensive experimental and careful clinical
investigations have led to the acceptance of BNCT,
confirming its efficacy in a clinical setting for brain,
thyroid, skin and recurrent head and neck tumors (13-16).
BNCT is a highly complex approach as a radiotherapy
modality and is considerably different from conventional
external beam therapy. In particular, BNCT facilities cannot
produce clean monoenergetic neutron radiation and thus the
beam is polluted with incident photons and neutrons with a
wide spectrum of energies. Thermal neutrons, present in the
free beam and higher energy neutrons (epithermal, fast
neutrons) are thermalized at the treatment depth and these
have different probabilities for capture reactions with
chemical elements within the human body. Further
contributions to the total dose arise from neutron–hydrogen
and neutron–nitrogen reactions. The sources for the total
absorbed dose include recoil protons from the scattering of
incident fast neutrons by hydrogen, protons emitted by the
14N (n, p) 14C neutron capture reaction, and incident
photons (gamma radiation) and photons generated in the 1H
(n,γ) 2H reaction (17). Photons generated in the irradiated
volume will also deposit an additional radiation dose not
only in the desired volume, but also to the surrounding
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tissues. The biological distribution of 10B also influences
the BNCT-related dose to tissue and consequently the total
dose distribution is contributed by several dose components.
Clinically useful BNCT requires a high 10B concentration in
the target volume with respect to neighboring healthy tissue
and a sufficiently high thermal neutron fluence. The most
important requirements for a BNCT delivery agent are low
systemic toxicity; selective uptake into the tumor cells;
rapid clearance from the blood and the tumor surrounding
normal tissues; long-lasting, high intratumoral concentration
(20 μg/g tumor)/>100 ppm) and a favorable intracellular
distribution, preferably in the cell nucleus.
First-generation boron compounds. The first clinical trials
for BNCT were started in the 1950s in the United States by
Sweet, Brownell and Farr (18-20) using simple boron agents
including sodium tetraborate (borax) (20), sodium
pentaborate, p-carboxyphenylboronic acid, or sodium
decahydrodecaborate (Na2B10H10) (21). The failure of
patient treatment (22, 23) due to serious treatment sequalae
caused both by low penetration of the thermal neutrons and
poor tumor/tissue selectivity of the boron delivery agents led
to the termination of BNCT in the US at that time. Some
decades later, after intensive radiobiological experiments,
early clinical research was performed using second-
generation boron compounds.
More recent renewed attention has been given to the first
simple compounds such as boric acid (BA, H3BO3). This
small weakly acidic compound is often used as a reference
compound for testing other boronated target molecules as it
has an accumulation efficiency in cells of 1 (24). This is due
to passive diffusion (confirmed by a study in frogs) (25). BA
also has no biological activity and has an elimination half-
life of 21 h (26). 
It has been shown that in GS-9L, U-343MGa, HeLa, V79
and B16 cells, BA distribution is even (27-29). There is,
however, favorable BA accumulation in bone and this has
potential for use for BNCT of osteosarcoma (30). There is
also a US patent for the use of BA in liver BNCT treatment
(US20130090513). A dose of about 5-60 mg of 10B stable
isotope per kilogram of patient body weight is used and then
the patient is irradiated 10-120 min after the injection when
measured blood concentrations of 10B stable isotope are
greater than 20-35 μg /ml. BA is the boron delivery agent
of choice for liver BNCT, as the other tested second-
generation boron compounds show a preference for
accumulation in the pancreas.
Second-generation boron compounds. The neurosurgeon
Hatanaka, upon his return to Japan from Sweet’s United
States research group, continued BNCT treatments in an
intraoperative setting (31, 32). In conjunction with Nakagawa,
he exposed the surgical cavity surface after brain tumor
removal to thermal neutrons in conjunction with BSH, which
has more selective accumulation in tumor cells. BSH uptake
is a passive process and shows transient binding, with a
biological half-life of the order of hours. This agent was the
first Food and Drug Administration (FDA)-approved BNCT
drug for human application (33). The most relevant human
evaluation on the biodistribution of BSH in tumor and normal
tissues was published regarding the European Organisation
for Research and Treatment of Cancer (EORTC) phase I trial
‘Postoperative treatment of glioblastoma with BNCT at the
Petten Irradiation Facility’ (protocol 11961). Twelve hours
after boron administration at 100 mg/kg or 22.9 mg/kg body
weight, the tumor/blood concentration ratios were 0.6±0.2
and 0.9±0.2, respectively (Table I). The highest boron uptake
was detected in the dura and there was an exceptionally low
uptake in bone, cerebrospinal fluid and in the brain. BSH is
safe for human applications at a dose of 100 mg BSH/kg
infused at 1 mg/kg/min for 4 consecutive days (34).   
Another BSH biodistribution and pharmacokinetic study
looked at 20 patients with high-grade gliomas and
confirmed the high interpatient variability of tumor boron
concentration and boron concentration in different regions
of the tumor (35).
Other representative results from the literature based on the
application of second-generation BNCT compounds are
summarized in Table I. The BSH dose is typically in the range
of 23 200 mg BSH/kg body weight. The use of BSH as a
BNCT agent was studied in different types of animal tumor
models, such as oral squamous cell carcinoma (36, 37),
pigmented melanoma, sarcoma (24) and pancreatic
adenocarcinoma in mouse and rat models (38). BSH has
already been applied in human clinical trials, such as for
patients with glioblastoma (34), with squamous cell carcinoma
of the head and neck (37), and in oral mucosal tissue (39).
Favorable 10B uptake for BNCT treatment would require
a tumor/normal tissue ratio greater than 2, and a tumor/blood
ratio greater than 0.6 for BSH (40). Table I shows that the
measured tumor/normal tissue ratio is frequently below 2 for
BSH. The tumor/blood ratio, however, is usually above 0.6
for BSH under the studied conditions.
Boron-containing amino acid (boronophenylalanine) (BPA)
was synthesized in 1958 by Snyder et al. (41) and was first
used in Japan for BNCT of melanoma (42). Clinical trials
were once more initiated in 1990s in the United States and
used the epithermal neutron beam at the Medical Research
Reactor and at Harvard-MIT. A soluble fructose complex,
BPA-F (concentration 400 mg/kg/2 h, i.v.) was used as the
boron delivery agent. It was postulated to be taken up by
active metabolic pathways in cells, resulting in favorable
tumor/blood and similar tumor/brain ratio of more than 1.5-
2 (43). The uptake of BPA into glioma and melanoma was
measured by tissue sampling in several clinical and
preclinical trials. Marked variability was detected in a study
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Table I. A summary of the main study parameters and results from representative publications.
Compound        Application            Cancer/            Route        Applied              Concentration                                Concentration ratio 
                                                          tissue                                  dose                       of 10B                                  
                                                           type                              (mg/kg bw)                  (μg/g)                         Tumor/blood               Tumor/normal tissue
BSH (34)             Human           Glioblastoma           i.v.             22.9               Tumor: 19.9±9.1          0.6±0.2 and 0.9±0.2                       NA
                                                                                                      100                       9.8±3.3
BSH (35)             Human          Glioblastoma,         i.v.    26.5, 44.1, 88.2          Tumor: 11.9                           NA                                  3.2-3.8
                                                    astrocytoma
BPA-F                 Human                Glioma               i.v.          290-450              Blood: 14-22                        3.8-4.4                               2.0-2.5
mediated (44)                                                                                                         Brain: 19-46
                                                                                                                               Tumor: 44-93
BPA (78)              Human             Melanoma             i.v.        179.7±14.9           Blood: 9.4±2.6                    3.40±0.83                                NA
BPA and              Human             SCC head             i.v.         BPA: 700                      NA                       BPA: 4.0±1.7 10B           BPA: Skin: 1.3±0.5, 
BSH (79)              and rat               and neck                           BSH: 200                                                  BSH1: 2±0.4 10B           Muscle: 2.1±1.2 and 
                                                                                                                                                                                                              Mucosa: 1.4±0.01
                                                                                                                                                                                                           BSH: Muscle: 3.6±0.6
                                                                                                                                                                                                           Lymph nodes: 2.5±1.0
                                                                                                                                                                                                                  Skin: 1.4±0.5
                                                                                                                                                                                                               Mucosa: 1.0±0.3
BSH and               Mice             Oral mucosal          i.p.         BSH: 55              BSH: 6.1±1.0              Epithelium/blood:                        NA
BPA (39)                                           tissue                              BPA: 700            BPA: 21.5±0.5                   BSH: 0.2:1
                                                                                                                                                                           BPA 1:1
L-BPA (80)         C3H/He             SCC-VII          s.c.; i.v.          500               Different tissues:           L-BPA 1.58±0.20                 Intestine: 1.31
                               Mice         xenograft on legs                                                        10-40                   L-FBPA: 1.52±0.42                 Liver: 1.77
                                                                                                                            Highest, kidney:                                                          Kidney: 0.46
                                                                                                                                       ~95                                                                       Lung: 1.34
                                                                                                                                                                                                                  Tongue: 1.36
                                                                                                                                                                                                                     Skin: 1.64
                                                                                                                                                                                                                  Muscle: 1.70
                                                                                                                                                                                                                    Brain: 4.24 
BPA (36)                Mice          Nude mice with       i.p.              250                  Tumor: 15.96                          6.44                            Tongue: 4.19
                                                       oral SCC                                                                                                                                               Skin: 4.68
                                                                                                                                                                                                                    Bone: 4.56 
BSH (36)               Mice          Nude mice with       i.p.               75                    Tumor: 3.61                           0.77                            Tongue: 1.05
                                                       oral SCC                                                                                                                                               Skin: 0.60
                                                                                                                                                                                                                    Bone: 0.59
                                                                                                                                                                                                                             
BPA (70)                Mice                Clear cell             i.v.              500               Dorsal tumor: 74           Dorsal: 9.2 at 1 h           Dorsal skin: 4.5 (1 h)
                                                        sarcoma                                                     Femoral tumor: 45       Femoral: 7.6 at 1.5 h     Femoral skin: 7.8 (1.5 h)
BPA (46)                Mice          Lung metastasis        i.v.               24          59.8±1.5 (Max. at 0.5 h)       3.4±0.6 at 0.5 h        Left lung: 8.7±6.0 at 0.5 h
                                                    of clear cell                                                                                            5.3±1.3 at 2.5 h              37.27±16.7 at 2.5 h
                                                      carcinoma
BPA (71)                 Rat               F98 Glioma/           i.v.               24           BPA: Glioma: 21.5±8.4              Glioma,                                 NA
                                                     melanoma-                                                 Melanoma: 28.6±4.6                BPA: 4.2
                                                     bearing rats                                                        cis-ABCPC:                cis-ABCPC: 3.9
                                                                                                                           Glioma: 26.2±9.7
                                                                                                                         Melanoma: 16.4±9.0
BPA (72)              In vitro      Human melanoma      i.p.              350               Tumor: 25.9± 2.6           Tumor/blood: 4.3               Tumor/skin: 2.5
                           and Mice     cell lines: MEL-J, 
                                                  A375, and M8.
BPA (81)                 Rat      Diffuse lung metastases  i.v.             300                 Tumor: ~25-50                        NA                                     NA
                                            from colon carcinoma                                                at ~60 min
BPA (82)             In vitro,         Osteosarcoma          i.v.              300              Tumor: 16.26±0.50                      NA                                    1.85
                                Rat
BPA, BSH,            Mice           B16 pigmented        i.p.      50-55 μg B/g        Cmax B16 tumor                       B16                                    B16
BA (24)                                     melanoma and                 for BA, BSH          BA: 43.2±2.2                       BA: 1.5                              BA: 1.8
                                                   RIF1 sarcoma                        and BPA             BSH: 28.1±4.9                    BSH: 1.8                           BSH: 1.8 
                                                                                                                              BPA: 55.0±4.5                     BPA: 3.2                            BPA: 3.2
BSH and BSH-       Mice               Pancreatic            i.v.              100          BSH polymer conjugate    Max. ~20 after 24 h                Muscle: 5-6
conjugates‡ (38)                         adenocarcinoma                                                    Tumor: ~90
SCC: Squamous cell cancer; PEG-b-P(Glu-SS-BSH): PEGylated-polyglutamic acid; L-BPA: 4-borono-L-phenylalanine; BPA-F: mediated fluoro-
borophenylalanine; BSH: sodium borcaptate; i.v. intravenous; cis-ABCPC: 1-amino-3-borono-cyclopentanecarboxylic acid; BA boric acid. i.p.
intraperitoneal; s.c.: subcutaneous.
using BPA-F involving 98 patients with glioma (44) (Table
I). A Japanese clinical study investigated the uptake of BPA
in squamous cell carcinoma of the head and neck showed a
promising 10B concentration and, for the first time,
demonstrated the change of boron concentration in the tumor
over time (36). All these investigations demonstrated
significantly larger tumor/normal tissue boron concentration
ratios when compared to BSH studies, e.g. 4.2-4.7 in oral
squamous cell carcinoma (36), 4.5-7.8 in clear cell sarcoma
(45), 8.7-37.3 in a lung metastasis model of clear cell
sarcoma (46), and 3.2 in B16 pigmented melanoma (24),
however with notable intra-individual and intertumoral
variability in boron concentration both in humans and in
rodent tumor models (Table I). BPA only has one boron atom
per molecule but can be applied at higher doses (180-700
mg/kg body weight) compared with BSH (23-200 mg/kg
body weight). Morris et al. applied 55 mg/kg BSH (30 mg
10B/kg) and 700 mg/kg BPA (34 mg 10B/kg) which resulted
in similar boron dosing and yet the BPA treatment resulted in
higher accumulated concentration of boron (6.1 versus
21.5 ppm) in oral mucosal tissue (39). High boron
concentrations were found in melanocytic malignant tumor
(74 mg 10B/kg wet tumor tissue) and in a lung metastasis
model of clear cell sarcoma (59.8 mg 10B/g). It is assumed
that BPA is selectively accumulated in cancer cells via 
L-amino acid transporter (LAT1)-mediated uptake (47, 48).
T98G and A172 glioblastoma cells were used in a recent
study published by Wada et al. in which the influence of
oxygen concentration on cell viability was investigated, as
well as the mRNA expression of LAT1 and the uptake of 
10B-BPA (49). It was concluded that hypoxia below 10% O2
significantly reduced the mRNA expression of LAT1 in both
cell lines. This means that reduced uptake of 10B-BPA in
glioblastoma in hypoxic conditions may be due to a lower
expression of this transporter protein. Wongthai et al. reported
that BPA is transported by amino acid transporter (ATB0,+),
and LAT1 and LAT2 aromatic amino acid transporters (50).
Subsequently, 18F-labeled BPA derivatives were used for
positron-emission tomography in order to determine the
pharmacokinetic parameters of BPA and to predict the
effectiveness of BNCT, as well as to detect post-treatment
radiation effects (51-53). 
BSH and BPA have been used independently or in
combination for decades in clinical studies in Japan, in the
US and in Europe (the multinational European trial, in Czech
Republic and in Finland) (34, 39, 40) for BNCT of patients
with high-grade glioma, melanoma and recurrent head and
neck cancer. The safety and feasibility for clinical
application of these two boron delivery agents was
established on the basis of the numerous preclinical and
clinical trials (40), although neither BSH, nor BPA-F proved
to be an optimal boron compound for BNCT.
Third-generation boron compounds. The considerable
requirements for boron delivery agents have resulted in the
need for further developments in order to achieve a more
selective, higher intra-tumoral boron concentration and long-
term intra-tumoral binding with favorable subcellular
localization, i.e. close to the cell nucleus. 
A collection of third-generation low- and high-molecular-
weight boron delivery agents is summarized in Table II (54).
Amongst the low-molecular-weight BNCT compounds, there
are boronated derivatives of other natural amino acids, such
as aspartic acid, tyrosine, cysteine, methionine and serine,
and boron-containing unnatural amino acids, e.g. designated
derivatives of 1-aminocyclobutane-1-carboxylic acid and 
1-amino-3-boronocyclopentanecarboxylic acid, and boron-
containing linear and cyclic peptides (55). These peptides
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Table II. A summary of third-generation boron delivery agents, novel compounds and their improved feature for boron neutron capture therapy.
Boron delivery agents (Ref)                                                                               Primary benefit
Boronated unnatural amino acids (54)                                                              Highly selectivity toward tumors 
Boronated cyclic peptides (55, 57)                                                                    Low toxicity and high tumor selectivity
Carbonyl nucleosides (56)                                                                                 High rate of phosphorylation into corresponding nucleotide
Boronated EGF and EGFR monoclonal antibodies (58)                                  High specificity for molecular targets such as EGFR 
Boronated DNA intercalators (83)                                                                     Binding to DNA
Boronated porphyrins (54, 61)                                                                           High tumor selectivity, long retention time
Transferrin-polyethylene glycol liposomes (65)                                               Increased boron uptake by tumor 
Boron-containing immunoliposomes and liposomes (58, 65)                         Effective large-scale transportation of small molecules 
Boron-containing nanoparticles, boron nitride nanotubes (66)                       High dispersibility in water
Boron containing lipiodol (84)                                                                          Soluble, high retention in hepatoma
Decaborone (GB10) (85)                                                                                   Non-toxic, homogeneous uptake in head and neck tumor
Dodecaborate cluster lipids and cholesterol derivatives (86)                          High tumor selectivity
Polyanionic polymers (38)                                                                                 Superior intratumoral penetration
EGF: Epidermal growth factor; EGFR: epidermal growth factor receptor; GB10 (Na210B10H10): non-toxic boron compound. 
were developed due to their low toxicity, high tissue-
penetrating properties (56) and increased water solubility
compared to BPA. 
Boronated linear and cyclic peptides have a low toxicity
and high tumor selectivity (57). In tumor cells, the ligands
for up-regulated receptors, especially epidermal growth
factor (EGFR), vascular endothelial growth factor (VEGFR)
and somatostatin receptors, are of particular interest (58).
Boron-containing purines, pyrimidines, thymidines,
nucleosides, and nucleotides have been investigated as boron
delivery agents, especially 3-carboranyl thymidine analogs.
For example, the 3-(dihydroxypropyl-carboranyl-pentyl)
thymidine derivate designated N5-2OH   has shown low
toxicity, selective tumor uptake, and high rate of
phosphorylation into the corresponding nucleotide (56).
Convection-enhanced delivery of N5-2OH was effective in
selectively delivering therapeutic amounts of boron to rats
bearing intracerebral implants of RG2 glioma (59). 
Another approach was to improve the delivery of second-
generation agents, using BSH lipiodol emulsion, BSH-
transferrin polyethylene glycol (PEG) liposomes, and BPA
derivatives with a higher percentage of boron by weight (60).
Boron-containing nucleosides and nucleotides, purines,
pyrimidines, thymidines (59) and boronated DNA
intercalators were designed to achieve high boron
concentration in or near to the cell nucleus. Boronated DNA-
binding molecules, e.g. alkylating agents, intercalators,
minor-groove binders, polyamines, derivatives of acridines,
Pt(II) complexes, tri-methoxyindoles, carboranylpolyamines
and metal complexes have been investigated and these
compounds typically have low tumor selectivity and
sometimes high toxicity due to their multiple cationic
charges and ability to bind to DNA (60).
Boronated carbohydrates, such as derivates of galactose,
glucose, lactose, maltose, mannose and ribose, have also
been investigated. These compounds usually display low
toxicity and poor tumor uptake, perhaps as a result of their
low hydrophobicity and a fast clearance from tissues (60).
A novel idea was to bind boron to porphyrin derivatives,
which have been already used for photodynamic therapy,
some with FDA approval, in order to establish dual tumor-
killing modality (54, 61). Several boron-containing
porphyrin derivatives, including chlorin, bacteriochlorin,
tetrabenzoporphyrin have been investigated as BNCT agents
(62) porphyrins of high-boron content. They are well-known,
non toxic, tumor-specific agents, which are exhibited several
superior features in comparison to BSH, BPA, such as
longer-lasting high tumor accumulation and high
tumor/brain, tumor/blood boron concentration ratios.
Boronated chlorins and bacterochlorins are promising agents
as dual BNCT and photodynamic therapy photosensitizers
due to a strong absorption of near-infrared light, which
penetrates deeper into human tissues. Boronated derivatives
of other amino acids, such as aspartic acid, tyrosine,
cysteine, methionine and serine, designated derivatives of 1-
aminocyclobutane-1-carboxylic acid and 1-amino-3-
boronocyclopentanecarboxylic acid and boron-containing
linear and cyclic peptides were developed because of their
low toxicity and high tissue-penetrating properties (63).
The radioresistance of hypoxic cells is well known (64),
therefore boron compounds with high capacity to accumulate
in hypoxic cells would be highly useful for BNCT of large
tumors. A boronated 2-nitroimidazole derivative (B-381) was
found to have a minimal cytotoxicity and preferentially
accumulate in hypoxic cells, and demonstrated longer tumor
retention in an in vivo glioma model compared to BPA. It
achieved significant tumor/normal tissue ratios as well as
tumor/blood ratios but suffered from extremely fast
elimination from plasma (64). 
Immunoliposomes have been shown to deliver small
boronated molecules such as BSH into brain tumors via
incorporation into the corresponding lipid bilayers (58).
Liposomes have been used to intracellularly transport large
amounts of boronated molecules e.g. PEG-based liposomes
and particles generally show increased tumor boron uptake
(65). High cellular boron concentrations can be achieved by
encapsulating low-molecular-weight compounds in tumor-
selective unilamellar liposomes. However, in vivo therapeutic
efficacy has yet to be demonstrated. These particles avoid
problems associated with leakage of encapsulated boronated
compounds and were shown to deliver large amounts of
boron to tumor-bearing mice with increased survival times
following BNCT (54). Other boron-containing nanoparticles
have also been proposed and investigated as delivery agents
for BNCT (66). 
Recently, novel nanotechniques, such as hollow boron
nitride nanospheres with potential for intratumoral boron
release from within the sphere, have produced nanoparticles
with promising results. Hexagonal BN has a high
dispersibility in water which makes this material useful for
BNCT (67). 
Boron Concentration Measurement 
and Distribution Imaging
A critical requirement at every stage in the development of
boronating agents for both BNCT and BPCEPT is the ability
to measure the concentration of and image the spatial
distribution of boron in biological samples and in living
organisms. A multidisciplinary, international effort has
resulted in various methods for measurement and imaging
boron in practical ways to enable BNCT dose calculation in
human treatment and establishing sophisticated techniques
for research on subcellular distribution analysis. Prompt
gamma-ray analysis (PGRA) is based on gamma-ray
spectroscopy following neutron capture in 10B, resulting in
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the emission of 478 keV photons. The photon emission rate
is proportional to the reaction rate of the neutron capture
reaction and therefore the 10B concentration. The emission
of 715 keV PGR due to BPC reaction is controversial, but
the same PGRA techniques can be used if there is an optimal
mixture of 10B and 11B and an appropriate neutron beam.
PGRA is fast and simple but requires a relatively large
sample and produces an average concentration of the sample.
Further application of PGRA for BNCT includes the
possibility of in vivo gamma-ray spectroscopy of the patient
during treatment. This method, however, needs further
improvement for implementation in a clinical routine.
Inductively coupled plasma-atomic emission spectroscopy
(ICP-AES) uses plasma to produce excited atoms that emit
electromagnetic radiation at a wavelength characteristic of a
particular element. ICP-mass spectrometry (MS) is a
combined method capable of monitoring isotopic speciation
for desired ions. ICP-AES and ICP-MS are rapid, reliable
methods for quantification of 10B concentration in
macroscopic samples; they have been used in conjunction
with BNCT for many years and can be applied for 11B
concentration determination for therapy with BPC. PGRA,
ICP-AES and ICP-MS measurements integrate the boron
concentration over a relatively large volume, therefore
individual boron distribution and subcellular boron
accumulation cannot be directly obtained. 
Further measuring techniques analyze the spatial
distribution of boron in a sample e.g. high-resolution alpha-
track autoradiography and neutron capture radiography result
in a similar resolution to histopathological imaging. Laser
microprobe mass analysis was the first technique to reach a
subcellular resolution in BNCT (68). Time-of-flight
secondary ion MS, particularly laser secondary neutral MS,
can quantitatively map the spatial boron distribution in
biological matrices with a sub-ppm detection limit. Electron
microscopic methods e.g. electron energy loss spectroscopy,
are less sensitive but have a much higher spatial resolution
(69). However, the latter methods are extremely time-, labor-
and cost-intensive (40). 
Another important aspect that has had only minimal
investigation is the metabolism of BPA and BSH that are
actually used in clinical trials for BNCT. Ion-trap MS in
combination with proteomic technologies offers a possibility
to investigate metabolites and transport of target molecules.
Such information is mandatory for optimizing the application
of these drugs on a scientifically solid basis. 18F-Labeling of
BPA and the use of positron-emission tomography to assess
the molecule in a patient and the detection of boron
compounds by magnetic resonance imaging might be feasible
(46, 70, 71). Positron-emission tomography with 18F-BPA has
been used for patient selection in recent clinical trials in Japan
(72) and Finland (29). It is essential in BPCEPT to be able to
measure the 11B concentration with a high resolution at
different time points relevant to proton irradiation in the
concerned target volume both for patient selection and for the
calculation of dose and biological effects. 
Boron Compounds for BPCEPT
Comparing the requirements for boron compounds for
BPCEPT and BNCT. The common feature of BNCT and
BPC is the binary nature of these high LET radiation
modalities requiring high intra-tumoral boron concentration
which is delivered by a non-toxic boronated agent. A suitable
compound can theoretically use the same chemical for both
types of treatment, but each enriched with suitable boron
isotope (10B for BNCT, 11B for BPC). However the optimal
boron delivery agent for BPCEPT should consider and take
into account the differences between BNCT and BPC (38).
BNCT is based on a reaction in which a thermal neutron
particle cannot be generated in a form of mono-particle,
monoenergetic beam specifically tailored to the target with
high accuracy. The BPC reaction is only considered as an
additional high LET dose component to standard proton
therapy. The cross section of proton boron fusion reaction is
about 0.9 barn with 675 keV resonant energy resulting in the
possibility of triggering a BPC reaction with extremely high
accuracy in the target even in the case of less selective boron
accumulation in the body. The much lower cross section of
the proton-boron capture reaction does however require a
much higher boron concentration to achieve a relevant
contribution to the proton dose. Furthermore, BNCT is
delivered in a single session or as 2-4 fractions after
intravenous infusion with boronated agent but in the majority
of proton irradiation cases, the dose is delivered with
conventional fractionation during 30-35 consecutive working
days. Therefore one of the most important requirements for
11B delivery agent is a long-lasting high intracellular
concentration as well as tolerability, which allows the
administration of the boron compound on weekly basis (9).
Strategies for 11B compound use and development for
BPCEPT. FDA-approved BSH and BPA are useful starting
agents for BPCEPT research. Different means of enhancing
bio-availability may result in an increase in intracellular
concentration and longer intracellular retention. The large
number of third-generation boron compounds developed for
BNCT has provided a basis for testing agents for BPCEPT
which have exhibited high boron delivery in the vicinity of the
cell nucleus, with favorable pharmacokinetic features. One
promising approach is the development of boronated nucleic
acids characterized by low cytotoxicity. Some types of high
boron-loaded DNA oligonucleotide modifications as potential
dual-action anticancer agents with antisense/anti-oxidant and
proposed BNCT activities might also work for BPCEPT. The
important biological features of these metallocarborane-
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modified DNA oligomers are their low cytotoxicity, increased
lipophilicity, formation of stable heteroduplexes with
complementary RNA strands and their function as effective
antisense oligonucleotides (73). These compounds deliver 11B
to the cell nuclei, therefore further increasing the biological
effect. Moreover, pro- and antioxidant activities were detected
depending on the concentration of the modified oligomer used.
The metallocarborane modification serves as an infrared-
sensitive nucleic acid label for detection. This approach may
be of importance for designing therapeutic nucleic acids both
for gene silencing as future biotherapeutics and for studies on
boron clusters as nucleic acid-modifying units for BPCEPT
(73).
Significantly higher tumor/normal tissue ratio for BSH can
be achieved by using a BSH-polymer conjugate [PEG-b-
poly(glutamic acid) copolymer]. The tumor/muscle tissue
ratio was about 5-6 for PEG-b-poly(glutamic acid)
copolymer-SS-BSH in subcutaneous human pancreatic
adenocarcinoma tumors in mice (Table I). High absolute
boron concentration (90 ppm) can be achieved in tumor
when BSH polymer conjugate is applied (38).
Some porphyrin derivatives have remarkably high
absolute intratumoral boron concentration and long retention
time, the two main prerequisites for efficient BPCEPT. Wu
et al. reported the synthesis of three copper (II)
tetracarboranylphenylporphyrins containing 40 or 80 boron
atoms per molecule (74). EMT-6 tumor-bearing mice were
given porphyrins in six i.p. injections (3/day within 8 h) over
a period of 2 days using a volume of 0.01 ml/g body weight
per injection. One of the porphyrins resulted in about 200
ppm tumor boron concentration after 2 days from the last
injection and 175 ppm after 4 days of the last injection.
Boron nitride nanotubes exhibit supermagnetic properties
and thus have potential as nanovectors for magnetic drug
targeting – the delivery of a drug with the required
concentration to the target site under the influence of an
external magnetic field (75, 76). The intended drug and a
suitable magnetically active carrier component would need to
be combined into a pharmacologically stable compound. The
intrinsic magnetic properties of coated boron nitride
nanotubes and their subsequent binding ability make them
highly suitable for use as targeted drug-delivery systems (76).
Hollow boron nitride spheres are also promising in cancer
therapy as a dual-action substrate. They show excellent water
solubility and degradability. Typical particle sizes are around
200 nm and they undergo further degradation, providing
enhanced permeability and retention effects, thereby enabling
passive targeting to tumor sites. A new therapeutic property
of hollow boron nitride spheres was demonstrated with
controlled release of boron for prostate cancer treatment.
Hollow boron nitride spheres induced apoptosis and inhibited
the proliferation of both androgen-sensitive and androgen-
independent prostate cancer cells (77).
Conclusion
BNCT was the first attempt at enhancing particle radiation
cancer treatment via an in situ nuclear reaction involving
boron-containing compounds. A large proportion of the
failures of this therapy arise from the quality of the neutron
beam. BPCEPT, an alternative therapy using high-quality
particle stream sources can overcome these issues. However,
the vast tome of research and clinical trials performed with
boron-containing compounds for BNCT can, with careful
scientific and medical guidance, be used to rapidly enhance
and direct research towards clinical applications of BPCEPT.
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